VTechWorks staff will be away for the winter holidays starting Tuesday, December 24, 2024, through Wednesday, January 1, 2025, and will not be replying to requests during this time. Thank you for your patience, and happy holidays!

Browsing by Author "Galaski, Johanna"

Now showing 1 - 2 of 2
  • Thumbnail Image
    CEACAM1 Activation by CbpF-Expressing E. coli
    Shhadeh, Amjad; Galaski, Johanna; Alon-Maimon, Tamar; Fahoum, Jamal; Wiener, Reuven; Slade, Daniel J.; Mandelboim, Ofer; Bachrach, Gilad (2021-07-29)
    Recent studies on the oral, anaerobic, gram-negative bacterium Fusobacterium nucleatum revealed its presence and involvement in colorectal, esophageal and breast cancer. We previously demonstrated that F. nucleatum binds and activates the human inhibitory receptors TIGIT and CEACAM1 leading to inhibition of T and NK cell anti-tumor immunity. CEACAM1 was found to be bound and activated by the fusobacterial trimeric autotransporter adhesin CbpF. Here we report the generation of a recombinant E. coli expressing full-length CbpF that efficiently binds and activates CEACAM1.
  • Thumbnail Image
    Fusobacterium nucleatum CbpF Mediates Inhibition of T Cell Function Through CEACAM1 Activation
    Galaski, Johanna; Shhadeh, Amjad; Umana, Ariana; Yoo, Christopher C.; Arpinati, Ludovica; Isaacson, Batya; Berhani, Orit; Singer, Bernhard B.; Slade, Daniel J.; Bachrach, Gilad; Mandelboim, Ofer (2021-07-15)
    F. nucleatum is an anaerobic bacterium that is associated with several tumor entities and promotes tumorigenesis. Recent evidence suggests that F. nucleatum binds the inhibitory receptor carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) via the trimeric autotransporter adhesin CbpF. However, whether this binding is functional or whether other fusobacterial trimeric autotransporter adhesins are involved in CEACAM1 activation is unknown. In this study, using F. nucleatum mutants lacking the type 5c trimeric autotransporter adhesins fvcA (CbpF), fvcB, fvcC, and fvcD, we show that F. nucleatum CbpF binds and activates CEACAM1 and also binds carcinoembryonic antigen (CEA), a tumor-associated protein. We further find that CEACAM antibodies directed against the CEACAM N-terminal domain block the CbpF-CEACAM1 interaction. In functional assays, we demonstrate CbpF-dependent inhibition of CD4(+) T cell response. Thus, we characterize an immune evasion mechanism in which F. nucleatum uses its surface protein CbpF to inhibit T cell function by activating CEACAM1.